13/06/2026
Drug of the Day: OLOPATADINE
1. Description (Pharmacological Class):
Olopatadine is a selective histamine H₁-receptor antagonist with mast cell‑stabilizing properties. It is an antiallergic agent available for topical (ophthalmic and intranasal) use.
2. Mechanism of Action:
Olopatadine competitively blocks histamine at H₁ receptor sites and inhibits the release of histamine from mast cells. It has negligible effects on α‑adrenergic, dopamine, and muscarinic receptors.
3. Indications:
· Allergic conjunctivitis (ophthalmic use): Symptomatic management of ocular itching associated with seasonal and perennial allergic conjunctivitis.
· Seasonal allergic rhinitis (nasal spray use): Relief of sneezing, rhinorrhea, nasal itching, and nasal congestion in patients ≥12 years of age (6 years for some formulations).
4. Contraindications:
None. However, caution is advised in patients with nasal disease (e.g., nasal ulceration, recurrent epistaxis), and in those with known hypersensitivity to olopatadine or any component of the formulation.
5. Safety in Pregnancy:
Pregnancy Category C (nasal spray). There are no adequate and well‑controlled studies in pregnant women. Use only if the potential benefit justifies the potential risk to the fetus. Due to low systemic exposure following ophthalmic use, overall risk is considered very low, but the standard precaution still applies.
6. Available Dosage Forms:
· Ophthalmic solution: 0.1%, 0.2%, or 0.7% single‑dose or multi‑dose bottles.
· Nasal spray: 0.6% solution in 30.5‑g bottles delivering ~665 mcg olopatadine HCl per metered spray.
· Oral tablets: Rarely available in some countries as 2.5 mg or 5 mg (not common in the US).
7. Common Side Effects:
· Local (ocular): Burning/stinging (5%), headache (7%), blurred vision, dry eye, foreign‑body sensation, keratitis.
· Local (nasal): Epistaxis (bleeding), nasal ulceration, bitter taste, pharyngolaryngeal pain, postnasal drip.
· Systemic (rare, due to minimal absorption): Somnolence (drowsiness) – 1‑4% across studies. Avoid driving or operating heavy machinery until you know how this drug affects you.
8. Drug Interactions
No clinically significant drug interactions have been identified (no CYP450 inhibition, negligible protein‑binding displacement, minimal systemic exposure after topical use).
9. Administration Tips:
· Ophthalmic: Wait ≥10 minutes before reinserting contact lenses; avoid touching dropper tip to eye or any surface.
· Nasal: Prime pump (5 sprays) before first use; if unused >7 days, reprime with 2 sprays. Do not spray into eyes. May cause bitter taste if sprayed with head tilted back.
